A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia
Public ClinicalTrials.gov record NCT03660774. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Evolving Treatment of Hemophilia's Impact on Neurodevelopment, Intelligence and Other Cognitive Functions (eTHINK)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The Hemophilia Growth and Development Study (HGDS) nearly 25 years ago showed haemophilia and HIV impacted brain development, thinking, and behaviour in children and adolescents. The eTHINK study is designed to understand whether advances in hemophilia treatment have removed any impact of hemophilia. If there still is an impact of hemophilia, the eTHINK study will help to identify which children or adolescents are still at risk, and how to screen other children. Participants and their child will participate in a comprehensive assessment of child's brain development, thinking and behavior through completing tests and questionnaires. There is only one study visit of 1 to 1.5 hours with no follow-up required
Study identification
- NCT ID
- NCT03660774
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 563 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 1 Year to 21 Years
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 27, 2018 (Actual)
- Primary completion
- Oct 11, 2019 (Actual)
- Completion
- Oct 11, 2019 (Actual)
- Last update posted
- Nov 22, 2019
2018 – 2019
United States locations
- U.S. sites
- 22
- U.S. states
- 19
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | Los Angeles | California | 90027 | — |
| Novo Nordisk Investigational Site | Orange | California | 92868 | — |
| Novo Nordisk Investigational Site | San Diego | California | 92123 | — |
| Novo Nordisk Investigational Site | Aurora | Colorado | 80045 | — |
| Novo Nordisk Investigational Site | Washington D.C. | District of Columbia | 20010-2978 | — |
| Novo Nordisk Investigational Site | Tampa | Florida | 33607 | — |
| Novo Nordisk Investigational Site | Atlanta | Georgia | 30322 | — |
| Novo Nordisk Investigational Site | Chicago | Illinois | 60612 | — |
| Novo Nordisk Investigational Site | Indianapolis | Indiana | 46260 | — |
| Novo Nordisk Investigational Site | New Orleans | Louisiana | 70112 | — |
| Novo Nordisk Investigational Site | Boston | Massachusetts | 02215 | — |
| Novo Nordisk Investigational Site | Ann Arbor | Michigan | 48105 | — |
| Novo Nordisk Investigational Site | Detroit | Michigan | 48201 | — |
| Novo Nordisk Investigational Site | Minneapolis | Minnesota | 55404 | — |
| Novo Nordisk Investigational Site | Omaha | Nebraska | 68198-6828 | — |
| Novo Nordisk Investigational Site | Charlotte | North Carolina | 28204 | — |
| Novo Nordisk Investigational Site | Cleveland | Ohio | 44106 | — |
| Novo Nordisk Investigational Site | Oklahoma City | Oklahoma | 73104 | — |
| Novo Nordisk Investigational Site | Philadelphia | Pennsylvania | 19134 | — |
| Novo Nordisk Investigational Site | Nashville | Tennessee | 37212 | — |
| Novo Nordisk Investigational Site | Salt Lake City | Utah | 84113 | — |
| Novo Nordisk Investigational Site | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03660774, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 22, 2019 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03660774 live on ClinicalTrials.gov.